CataloniaBio & HealthTech has awarded biotechnology company IMIDomics with the Bioèxit Award for their exemplary transition from the clinic to a company and, in particular, for the milestones achieved in funding during 2021 in the field of biomedicine and health in Catalonia. The ceremony took place March 22 as part of the CataloniaBio & HealthTech Gala at the Palau de la Música in Barcelona, which was attended by the Catalan Minister of Health, Josep Maria Argimon, and by more than 250 members of the association, including entrepreneurs, executives, and investors in the sector.
The jury especially valued IMIDomics' ability to raise international funds during 2021. The biotechnology company, a spin-off of Vall d'Hebron, raised 14 million euros last July, with the leading investors beingthe American firm DNS Capital, with the participation of thepharmaceutical company Brystol Myers Squibb, The Pritzker Organization and TAO Capital, among others. IMIDomics is working on discovering and developing new drugs for treating immune-mediated inflammatory diseases and has created the IMIDomics Precision Discovery Platform to promote precision medicine in this therapeutic field and respond to needs that have not yet been met. In this sense, the jury also highlighted the trajectory of IMIDomics as a paradigmatic and successful example of transitioning from a clinic to a company.
Sara Marsal, IMIDomics co-founderand CMO, gave thanks for the award via video from San Francisco, where she is working on the company’s strategic plan. On behalf of the company, Toni Julià accepted the award from the Minister of Health of the Generalitat de Catalunya, Josep Maria Argimon. Marsal appreciated the support received from everyone present, patients and all who have accompanied them as the company grew throughout these years: "IMIDomics is a collective project and I cannot conceive of this award but as a recognition to all those who have made it possible”. She reflected on entrepreneurship, saying that "it is not an easy or risk-free journey". "If I look back and thinka bout the reasons for our success, I would point at having a global and international approach from the beginning, excellence in all we do, teamwork and confidence in people," she added.
To date, the Bioèxit Award has been given to Oryzon (2015), Minoryx Therapeutics and Palobiofarma (2016), STAT-Dx and Mosaic Biomedicals (2017), Anaconda Biomed and Mind the Byte (2018), Ysios Capital and Antonio Parente (2019). ), Kymos (2020) and ONA Therapeutics (2021).
Comments